Ascensia Diabetes Care announced today that it expanded the Eversense PASS program for the Senseonics (NYSE:SENS) Eversense E3 CGM.
Eversense PASS, a payment assistance and simple savings program, aims to enhance affordability and access to Eversense E3. Ascensia serves as the global commercial partner for Senseonics. The Senseonics continuous glucose monitor (CGM), a 180-day implantable CGM, received FDA approval in February of last year.
It features a third-generation sensor with SBA technology that enhances sensor longevity. This makes it — according to Senseonics — the longest-lasting CGM system. The fully implantable sensor requires just two insertion and removal procedures per year.
Get the full story at our sister site, Drug Delivery Business News.